Latest Breaking News On - Phase 2 innovatv 204 - Page 1 : comparemela.com

The MAA seeking the approval of tisotumab vedotin in select patients with recurrent or metastatic cervical cancer has been validated by the EMA.

United statesGonzalez martinEuropean medicines agencyMarketing authorization applicationTisotumab vedotinAntibody drug conjugateCervical cancerGynecologic cancerPhase 3 innovatv 301 trialPhase 2 innovatv 204